Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Net Margin (2016 - 2025)

Zevra Therapeutics' Net Margin history spans 9 years, with the latest figure at 35.62% for Q4 2025.

  • For Q4 2025, Net Margin rose 33267.0% year-over-year to 35.62%; the TTM value through Dec 2025 reached 78.11%, up 52566.0%, while the annual FY2025 figure was 78.15%, 52523.0% up from the prior year.
  • Net Margin reached 35.62% in Q4 2025 per ZVRA's latest filing, up from 2.08% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 288.44% in Q2 2025 to a low of 5378.86% in Q3 2022.
  • Average Net Margin over 5 years is 542.65%, with a median of 129.32% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -528935bps in 2022, then skyrocketed 502076bps in 2023.
  • A 5-year view of Net Margin shows it stood at 104.69% in 2021, then grew by 14bps to 90.3% in 2022, then crashed by -71bps to 153.96% in 2023, then crashed by -93bps to 297.06% in 2024, then soared by 112bps to 35.62% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Net Margin are 35.62% (Q4 2025), 2.08% (Q3 2025), and 288.44% (Q2 2025).